Table 2.
Adverse events profiles among treatment groups
| Placebo (N=18) |
Sertraline (N=19) |
R. rosea (N=20) |
P-value | |
|---|---|---|---|---|
| # (%) of subjects experienced AE | 3 (17) | 12(63) | 6 (30) | 0.012 |
|
| ||||
| Total # of AEs experienced* | 14 | 52 | 12 | |
| -Nausea | 0 | 10 | 0 | |
| -Sexual dysfunction | 0 | 7 | 0 | |
| -Appetite change | 0 | 4 | 0 | |
| -Insomnia | 0 | 4 | 0 | |
| -Palpatations | 0 | 3 | 0 | |
| -Gastrointestinal disturbance | 0 | 3 | 0 | |
| -Yawning | 0 | 3 | 0 | |
| -Dry mouth | 0 | 2 | 0 | |
| -Fatigue | 0 | 2 | 0 | |
| -Headache | 0 | 2 | 0 | |
| -Nervousness | 2 | 2 | 2 | |
| -Dizziness | 0 | 0 | 2 | |
*
Only adverse events experienced by more than 1 subject were listed in the table.